The lawsuit alleges that the companies failed to warn the consumers of Actos regarding the increased risk of bladder cancer associated with pioglitazone, sold under the brand name Actos.
Earlier in June 2011, the US Food and Drug Administration (FDA) has issued safety alert in connection with the risk of bladder cancer with prolonged usage of Actos.
One of the lead attorneys litigating the case AJ De Bartolomeo said prescription drug manufacturers are required to issue warnings about the possible risks of negative side effects from their products.
"When a manufacturer decides not to provide full disclosure of the potential risks from a medication, doctors and patients cannot make informed decisions about what drug is right for them, and as a result, people suffer injuries unnecessarily," Bartolomeo said.